| Sep 3 |
Coya Therapeutics to Present at Upcoming Healthcare Conferences
|
| Aug 19 |
Coya Therapeutics Promotes Arun Swaminathan Ph.D. to Chief Executive Officer Effective November 1st, 2024
|
| Aug 12 |
Coya Therapeutics GAAP EPS of -$0.19, revenue of $3.43M
|
| Aug 12 |
Coya Therapeutics Provides a Corporate Update and Reports Unaudited Second Quarter 2024 Financial Results
|
| Aug 2 |
Coya Therapeutics Announces that Results from a Double-Blind Placebo-Controlled Study in Alzheimer’s Disease will be presented on October 29, 2024 at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid
|
| Jul 31 |
Coya Therapeutics Expands Pipeline and Intellectual Property Portfolio with Filing of New U.S. Patents for COYA 301 in Combination with Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
|
| Jun 20 |
Coya Therapeutics Expands Sponsored Research Collaboration with Houston Methodist Research Institute Along with Funding from the Johnson Center for Cellular Therapeutics to Advance Regulatory T Cell Exosome Platform into the Clinic
|
| Jun 14 |
Coya Therapeutics files to sell 603K common shares for holders
|
| Jun 11 |
Coya gains as peer-reviewed data highlights potential of ALS therapy
|
| Jun 11 |
Coya Therapeutics Announces Publication of ALS Study in Peer-Reviewed Journal Frontiers in Neurology
|
